|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Long J, Luo GP, Xiao ZW, Liu ZQ, Guo M,
Liu L, Liu C, Xu J, Gao YT, Zheng Y, et al: Cancer statistics:
Current diagnosis and treatment of pancreatic cancer in Shanghai,
China. Cancer Lett. 346:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petekkaya I, Ayyildiz V, Kizilarslanoglu
MC, Sahin U, Gezgen G, Roach EC, Karcaaltincaba M and Altundag K:
Prognosis of breast cancer in patients with peritoneal metastasis.
Breast. 21:420–421. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S,
Fells J, Uchiyama A, Murakami-Murofushi K, Kennel S, Wall J, et al:
Controlling cancer through the autotaxin-lysophosphatidic acid
receptor axis. Biochem Soc Trans. 40:31–36. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chun J, Hla T, Lynch KR, Spiegel S and
Moolenaar WH: International Union of Basic and Clinical
Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.
Pharmacol Rev. 62:579–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sedláková I, Vávrová J, Tošner J and
Hanousek L: Lysophosphatidic acid (LPA) - a perspective marker in
ovarian cancer. Tumour Biol. 32:311–316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun K, Cai H, Duan X, Yang Y, Li M, Qu J,
Zhang X and Wang J: Aberrant expression and potential therapeutic
target of lysophosphatidic acid receptor 3 in triple-negative
breast cancers. Clin Exp Med. 15:371–380. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun K, Duan X, Cai H, Liu X, Yang Y, Li M,
Zhang X and Wang J: Curcumin inhibits LPA-induced invasion by
attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells.
Clin Exp Med. 16:37–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kitayama J, Shida D, Sako A, Ishikawa M,
Hama K, Aoki J, Arai H and Nagawa H: Over-expression of
lysophosphatidic acid receptor-2 in human invasive ductal
carcinoma. Breast Cancer Res. 6:R640–R646. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bos R, van der Groep P, Greijer AE,
Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ and van
der Wall E: Levels of hypoxia-inducible factor-1alpha independently
predict prognosis in patients with lymph node negative breast
carcinoma. Cancer. 97:1573–1581. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Span PN and Bussink J: Biology of hypoxia.
Semin Nucl Med. 45:101–109. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fransén K, Fenech M, Fredrikson M,
Dabrosin C and Söderkvist P: Association between ulcerative growth
and hypoxia inducible factor-1alpha polymorphisms in colorectal
cancer patients. Mol Carcinog. 45:833–840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Putra AC, Tanimoto K, Arifin M and Hiyama
K: Hypoxia-inducible factor-1α polymorphisms are associated with
genetic aberrations in lung cancer. Respirology. 16:796–802. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Amelio I and Melino G: The ‘Sharp’ blade
against HIF-mediated metastasis. Cell Cycle. 11:4530–4535. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piccolo S, Enzo E and Montagner M: p63,
Sharp1, and HIFs: Master regulators of metastasis in
triple-negative breast cancer. Cancer Res. 73:4978–4981. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ke Q and Costa M: Hypoxia-inducible
factor-1 (HIF-1). Mol Pharmacol. 70:1469–1480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bernaudin M, Tang Y, Reilly M, Petit E and
Sharp FR: Brain genomic response following hypoxia and
re-oxygenation in the neonatal rat. Identification of genes that
may contribute to hypoxia-induced ischemic tolerance. J Biol Chem.
277:39728–39738. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Badowska-Kozakiewicz AM, Budzik MP and
Przybylski J: Hypoxia in breast cancer. Pol J Pathol. 66:337–346.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huanna T, Tao Z, Xiangfei W, Longfei A,
Yuanyuan X, Jianhua W, Cuifang Z, Manjing J, Wenjing C, Shaochuan
Q, et al: GALNT14 mediates tumor invasion and migration in breast
cancer cell MCF-7. Mol Carcinog. 54:1159–1171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi JW, Herr DR, Noguchi K, Yung YC, Lee
CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, et al: LPA
receptors: Subtypes and biological actions. Annu Rev Pharmacol
Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W,
Zhang F, Yu S, Stephens LC, Cui X, Murrow G, et al: Expression of
autotaxin and lysophosphatidic acid receptors increases mammary
tumorigenesis, invasion, and metastases. Cancer Cell. 15:539–550.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JW, Bae SH, Jeong JW, Kim SH and Kim
KW: Hypoxia-inducible factor (HIF-1)α: Its protein stability and
biological functions. Exp Mol Med. 36:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Birner P, Gatterbauer B, Oberhuber G,
Schindl M, Rössler K, Prodinger A, Budka H and Hainfellner JA:
Expression of hypoxia-inducible factor-1 alpha in
oligodendrogliomas: Its impact on prognosis and on neoangiogenesis.
Cancer. 92:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu H, Forbes RA and Verma A:
Hypoxia-inducible factor 1 activation by aerobic glycolysis
implicates the Warburg effect in carcinogenesis. J Biol Chem.
277:23111–23115. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Montagner M, Enzo E, Forcato M, Zanconato
F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et
al: SHARP1 suppresses breast cancer metastasis by promoting
degradation of hypoxia-inducible factors. Nature. 487:380–384.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bertout JA, Patel SA and Simon MC: The
impact of O2 availability on human cancer. Nat Rev
Cancer. 8:967–975. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen M, Towers LN and O'Connor KL: LPA2
(EDG4) mediates Rho-dependent chemotaxis with lower efficacy than
LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol.
292:C1927–C1933. 2007. View Article : Google Scholar : PubMed/NCBI
|
